Human Milk Oligosaccharides Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

Publisher Fortune Business Insights Pvt. Ltd.

Published Mar 01, 2026

Length 180 Pages

SKU # FOB21036902

Description

Growth Factors of Human Milk Oligosaccharides (HMO) Market

The global Human Milk Oligosaccharides (HMO) market is witnessing rapid expansion, driven by growing awareness of infant nutrition, scientific validation of health benefits, and increasing adoption of premium functional ingredients by infant formula manufacturers. According to the report timeline, the global human milk oligosaccharides market size was valued at USD 275.34 million in 2025. The market is projected to grow to USD 308.68 million in 2026, supported by rising investments in biotechnology, food innovation, and infant health research. Over the long-term forecast period, the market is expected to reach USD 1,405.51 million by 2034, reflecting strong global demand across infant nutrition, functional foods, and dietary supplements.

Human Milk Oligosaccharides are complex carbohydrates naturally present in human breast milk and are critical for infant immune system development, gut microbiome balance, and protection against pathogens. Due to their proven biological functionality, HMOs are increasingly incorporated into infant formulas and nutrition products by major manufacturers such as Abbott Laboratories and Nestlé S.A., strengthening market growth worldwide.

Market Dynamics

One of the primary drivers of the human milk oligosaccharides market is the growing demand for premium ingredients in infant nutrition products. Parents are increasingly prioritizing scientifically backed nutrition solutions to support healthy growth, immunity, and cognitive development in infants. Clinical research has demonstrated that HMOs help reduce infection risks, improve digestion, and enhance brain development, which has significantly increased their adoption in infant formulas.

Another key growth driver is the rise in strategic alliances and research collaborations. Market players are forming partnerships with academic institutions, biotechnology firms, and ingredient manufacturers to enhance production capabilities and accelerate innovation. These collaborations support the development of cost-efficient, scalable, and non-GMO production technologies, which further strengthen market penetration.

However, the market faces restraints due to the complex manufacturing process and high raw material costs. The synthesis and isolation of HMOs require advanced fermentation and biotechnology processes, making large-scale production capital-intensive. Fluctuations in raw material prices, particularly lactose, also impact overall production economics.

Market Opportunities and Challenges

The increasing consumer spending on healthy and premium nutrition products presents significant growth opportunities for the human milk oligosaccharides market. Emerging economies such as China, India, Brazil, and Southeast Asian countries are witnessing rising disposable incomes and growing awareness of infant nutrition, creating a favorable environment for HMO-based products.

At the same time, slow and stringent regulatory approval processes pose a challenge to market growth. While regions such as North America and Europe have established regulatory frameworks for HMOs, many developing regions still lack clear guidelines, which delays product approvals and market entry.

Segmentation Analysis

By type, 2’-Fucosyllactose (2’FL) dominated the market, accounting for 67% share in 2024, owing to its extensive clinical research, industrial scalability, and proven benefits in gut and immune health. Other types such as LNT, 3’FL, 3’SL, and 6’SL are gaining attention as research activity increases.

By structure, Neutral Fucosylated HMOs held the largest market share in 2024, supported by their abundance and functional benefits in infant nutrition. By application, infant nutrition accounted for 82% of the market share in 2025, driven by rising consumption of fortified infant formulas.

Regional Outlook

North America dominated the human milk oligosaccharides market with a 46.86% share in 2025, supported by strong research infrastructure, early adoption of novel food ingredients, and high demand for functional infant nutrition. Europe followed as the second-largest market, benefiting from strict food safety regulations and growing use of HMOs in infant formulas and dietary supplements. Asia Pacific is emerging as a high-growth region due to rising fertility rates, increasing disposable income, and expanding awareness of infant health in countries such as China and India.

Competitive Landscape

The global human milk oligosaccharides market is moderately consolidated, with leading players such as DSM, BASF SE, Chr. Hansen A/S, International Flavors & Fragrances Inc., and FrieslandCampina focusing on R&D investments, acquisitions, and product innovation to strengthen their market position.

Conclusion

Aligned strictly with the report years of 2025, 2026, and 2034, the global human milk oligosaccharides market shows exceptional long-term growth potential. Rising demand for premium infant nutrition, strong scientific validation of health benefits, expanding regulatory approvals, and continuous technological advancements are expected to sustain market momentum. Despite challenges related to production complexity and regulatory timelines, the market is well-positioned for robust expansion as HMOs become an integral component of next-generation nutrition solutions worldwide.

ATTRIBUTE DETAILS

Study Period 2021-2034

Base Year 2025

Forecast Period 2026-2034

Historical Period 2021-2024

Growth Rate CAGR of 20.86% from 2026 to 2034

Unit Value (USD million)

Segmentation By Type

2’FL

3’FL

3’SL

6’SL

LNT

By Structure

Neutral Fucosylated HMOs

Neutral HMOs

Sialylated HMOs

By Application

Infant Nutrition

Functional Food and Beverages

Food Supplements

Pharmaceuticals

By Region

North America (by Type, by Structure, By Application and by country)

· U.S. (By Application)

· Canada (By Application)

· Mexico (By Application)

Europe (by Type, by Structure, By Application and by country)

· U.K. (By Application)

· Germany (By Application)

· France (By Application)

· Spain (By Application)

· Italy (By Application)

· Rest of Europe (By Application)

Asia Pacific (by Type, by Structure, By Application and by country)

· China (By Application)

· India (By Application)

· Japan (By Application)

· Australia (By Application)

· Rest of Asia Pacific (By Application)

Rest of the World (by Type, by Structure, By Application and by country)

· Brazil (By Application)

· Argentina (By Application)

· Israel (By Application)

· Saudi Arabia (By Application)

· Other Countries (By Application)

Please Note: It will take 2-3 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Research Scope; 1.2. Market Segmentation; 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Overview on the Parent Market; 4.2. Industry SWOT Analysis; 4.3. Regulatory Framework for the Market; 4.4. Recent Industry Developments - Policies, Mergers & Acquisitions, and New Product Launches; 4.5. Impact of COVID-19 on this market
5. Global Human Milk Oligosaccharides Market Analysis, Insights and Forecast, 2021-2034: 5.1. Key Findings / Summary; 5.2. Market Size Estimates and Forecast; 5.2.1. By Type (Value); 5.2.1.1. 2’FL; 5.2.1.2. 3’FL; 5.2.1.3. 3’SL; 5.2.1.4. 6’SL; 5.2.1.5. LNT; 5.2.2. By Structure (Value); 5.2.2.1. Neutral Fucosylated HMOs; 5.2.2.2. Neutral HMOs; 5.2.2.3. Sialylated HMOs; 5.2.3. By Application (Value); 5.2.3.1. Infant Nutrition; 5.2.3.2. Functional food and beverages; 5.2.3.3. Food Supplements; 5.2.3.4. Pharmaceuticals; 5.2.4. By Region (Value); 5.2.4.1. North America; 5.2.4.2. Europe; 5.2.4.3. Asia Pacific; 5.2.4.4. Rest of the World; 5.2.4.5. Middle East & Africa
6. North America Human Milk Oligosaccharides Market Analysis, Insights and Forecast, 2021-2034: 6.1. Key Findings / Summary; 6.2. Market Size Estimates and Forecast; 6.2.1. By Type (Value); 6.2.1.1. 2’FL; 6.2.1.2. 3’FL; 6.2.1.3. 3’SL; 6.2.1.4. 6’SL; 6.2.1.5. LNT; 6.2.2. By Structure (Value); 6.2.2.1. Neutral Fucosylated HMOs; 6.2.2.2. Neutral HMOs; 6.2.2.3. Sialylated HMOs; 6.2.3. By Application (Value); 6.2.3.1. Infant Nutrition; 6.2.3.2. Functional food and beverages; 6.2.3.3. Food Supplements; 6.2.3.4. Pharmaceuticals; 6.2.4. By Country (Value); 6.2.4.1. The U.S.; 6.2.4.1.1. By Application (Value); 6.2.4.1.1.1. Infant Nutrition; 6.2.4.1.1.2. Functional food and beverages; 6.2.4.1.1.3. Food Supplements; 6.2.4.1.1.4. Pharmaceuticals; 6.2.4.2. Canada; 6.2.4.2.1. By Application (Value); 6.2.4.2.1.1. Infant Nutrition; 6.2.4.2.1.2. Functional food and beverages; 6.2.4.2.1.3. Food Supplements; 6.2.4.2.1.4. Pharmaceuticals; 6.2.4.3. Mexico; 6.2.4.3.1. By Application (Value); 6.2.4.3.1.1. Infant Nutrition; 6.2.4.3.1.2. Functional food and beverages; 6.2.4.3.1.3. Food Supplements; 6.2.4.3.1.4. Pharmaceuticals
7. Europe Human Milk Oligosaccharides Market Analysis, Insights and Forecast, 2021-2034: 7.1. Key Findings / Summary; 7.2. Market Size Estimates and Forecast; 7.2.1. By Type (Value); 7.2.1.1. 2’FL; 7.2.1.2. 3’FL; 7.2.1.3. 3’SL; 7.2.1.4. 6’SL; 7.2.1.5. LNT; 7.2.2. By Structure (Value); 7.2.2.1. Neutral Fucosylated HMOs; 7.2.2.2. Neutral HMOs; 7.2.2.3. Sialylated HMOs; 7.2.3. By Application (Value); 7.2.3.1. Infant Nutrition; 7.2.3.2. Functional food and beverages; 7.2.3.3. Food Supplements; 7.2.3.4. Pharmaceuticals; 7.2.4. By Country (Value); 7.2.4.1. Germany; 7.2.4.1.1. By Application (Value); 7.2.4.1.1.1. Infant Nutrition; 7.2.4.1.1.2. Functional food and beverages; 7.2.4.1.1.3. Food Supplements; 7.2.4.1.1.4. Pharmaceuticals; 7.2.4.2. U.K.; 7.2.4.2.1. By Application (Value); 7.2.4.2.1.1. Infant Nutrition; 7.2.4.2.1.2. Functional food and beverages; 7.2.4.2.1.3. Food Supplements; 7.2.4.2.1.4. Pharmaceuticals; 7.2.4.3. France; 7.2.4.3.1. By Application (Value); 7.2.4.3.1.1. Infant Nutrition; 7.2.4.3.1.2. Functional food and beverages; 7.2.4.3.1.3. Food Supplements; 7.2.4.3.1.4. Pharmaceuticals; 7.2.4.4. Spain; 7.2.4.4.1. By Application (Value); 7.2.4.4.1.1. Infant Nutrition; 7.2.4.4.1.2. Functional food and beverages; 7.2.4.4.1.3. Food Supplements; 7.2.4.4.1.4. Pharmaceuticals; 7.2.4.5. Italy; 7.2.4.5.1. By Application (Value); 7.2.4.5.1.1. Infant Nutrition; 7.2.4.5.1.2. Functional food and beverages; 7.2.4.5.1.3. Food Supplements; 7.2.4.5.1.4. Pharmaceuticals; 7.2.4.6. Rest of Europe; 7.2.4.6.1. By Application (Value); 7.2.4.6.1.1. Infant Nutrition; 7.2.4.6.1.2. Functional food and beverages; 7.2.4.6.1.3. Food Supplements; 7.2.4.6.1.4. Pharmaceuticals
8. Asia Pacific Human Milk Oligosaccharides Market Analysis, Insights and Forecast, 2021-2034: 8.1. Key Findings / Summary; 8.2. Market Size Estimates and Forecast; 8.2.1. By Type (Value); 8.2.1.1. 2’FL; 8.2.1.2. 3’FL; 8.2.1.3. 3’SL; 8.2.1.4. 6’SL; 8.2.1.5. LNT; 8.2.2. By Structure (Value); 8.2.2.1. Neutral Fucosylated HMOs; 8.2.2.2. Neutral HMOs; 8.2.2.3. Sialylated HMOs; 8.2.3. By Application (Value); 8.2.3.1. Infant Nutrition; 8.2.3.2. Functional food and beverages; 8.2.3.3. Food Supplements; 8.2.3.4. Pharmaceuticals; 8.2.4. By Country (Value); 8.2.4.1. China; 8.2.4.1.1. By Application (Value); 8.2.4.1.1.1. Infant Nutrition; 8.2.4.1.1.2. Functional food and beverages; 8.2.4.1.1.3. Food Supplements; 8.2.4.1.1.4. Pharmaceuticals; 8.2.4.2. India; 8.2.4.2.1. By Application (Value); 8.2.4.2.1.1. Infant Nutrition; 8.2.4.2.1.2. Functional food and beverages; 8.2.4.2.1.3. Food Supplements; 8.2.4.2.1.4. Pharmaceuticals; 8.2.4.3. Japan; 8.2.4.3.1. By Application (Value); 8.2.4.3.1.1. Infant Nutrition; 8.2.4.3.1.2. Functional food and beverages; 8.2.4.3.1.3. Food Supplements; 8.2.4.3.1.4. Pharmaceuticals; 8.2.4.4. Australia; 8.2.4.4.1. By Application (Value); 8.2.4.4.1.1. Infant Nutrition; 8.2.4.4.1.2. Functional food and beverages; 8.2.4.4.1.3. Food Supplements; 8.2.4.4.1.4. Pharmaceuticals; 8.2.4.5. Rest of APAC; 8.2.4.5.1. By Application (Value); 8.2.4.5.1.1. Infant Nutrition; 8.2.4.5.1.2. Functional food and beverages; 8.2.4.5.1.3. Food Supplements; 8.2.4.5.1.4. Pharmaceuticals
9. Rest of the World Human Milk Oligosaccharides Market Analysis, Insights and Forecast, 2021-2034: 9.1. Key Findings / Summary; 9.2. Market Size Estimates and Forecast; 9.2.1. By Type (Value); 9.2.1.1. 2’FL; 9.2.1.2. 3’FL; 9.2.1.3. 3’SL; 9.2.1.4. 6’SL; 9.2.1.5. LNT; 9.2.2. By Structure (Value); 9.2.2.1. Neutral Fucosylated HMOs; 9.2.2.2. Neutral HMOs; 9.2.2.3. Sialylated HMOs; 9.2.3. By Application (Value); 9.2.3.1. Infant Nutrition; 9.2.3.2. Functional food and beverages; 9.2.3.3. Food Supplements; 9.2.3.4. Pharmaceuticals; 9.3. By Country (Value); 9.3.1. Brazil; 9.3.1.1. By Application (Value); 9.3.1.1.1. Infant Nutrition; 9.3.1.1.2. Functional food and beverages; 9.3.1.1.3. Food Supplements; 9.3.1.1.4. Pharmaceuticals; 9.3.2. Argentina; 9.3.2.1. By Application (Value); 9.3.2.1.1. Infant Nutrition; 9.3.2.1.2. Functional food and beverages; 9.3.2.1.3. Food Supplements; 9.3.2.1.4. Pharmaceuticals; 9.3.3. Saudi Arabia; 9.3.3.1. By Application (Value); 9.3.3.1.1. Infant Nutrition; 9.3.3.1.2. Functional food and beverages; 9.3.3.1.3. Food Supplements; 9.3.3.1.4. Pharmaceuticals; 9.3.4. Israel; 9.3.4.1. By Application (Value); 9.3.4.1.1. Infant Nutrition; 9.3.4.1.2. Functional food and beverages; 9.3.4.1.3. Food Supplements; 9.3.4.1.4. Pharmaceuticals; 9.3.5. Other Countries; 9.3.5.1. By Application (Value); 9.3.5.1.1. Infant Nutrition; 9.3.5.1.2. Functional food and beverages; 9.3.5.1.3. Food Supplements; 9.3.5.1.4. Pharmaceuticals
10. Competitive Matrix: 10.1. Business Strategies Adopted by Leading Players; 10.2. Global Human Milk Oligosaccharides Market Ranking Analysis, By Key Manufacturer, 2025
11. Company Profiles: 11.1. Koninklijke DSM N.V.; 11.1.1. Overview; 11.1.2. Description; 11.1.3. Product Portfolio; 11.1.4. Financials (Data as available in public domain and/or on paid databases); 11.1.5. Recent Developments; 11.2. BASF SE; 11.3. Chr. Hansen A/S; 11.4. International Flavors and Fragrances Inc.; 11.5. FrieslandCampina.; 11.6. KYOWA HAKKO BIO CO.,LTD.; 11.7. Dextra Laboratories.; 11.8. Inboise N.V.; 11.9. ELICITYL S.A; 11.10. Abbott Laboratories

Pricing

Currency Rates

Single User Email from Publisher $4,850
Global Site License Email from Publisher $6,850

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now